Top Pharmaceutical Companies in Los Angeles, CA (91)
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Product Line Growth: Feedback suggests newer offerings like Pharma Direct and subscriptions are expanding rapidly, indicating momentum beyond the legacy prescription-discount model.
Strategic Partnerships: Feedback suggests deepening relationships with pharmaceutical manufacturers are driving strong growth in Pharma Direct and expanding medication-access programs.
Healthy Cash Flow: Feedback suggests operating cash flow was strong in recent periods, even as total revenue was near flat and segment performance was mixed.
Best Formulations is a contract manufacturer specializing in the development and production of nutraceuticals, dietary supplements, and personal care products. Founded in 1984, the company provides manufacturing services for vitamins, minerals, and plant-based nutritional supplements. Following its acquisition by Sirio Pharma, it serves as a key manufacturing hub for global health and wellness brands, with operations spanning nutraceuticals and beauty...
Seragon is a research-based biopharmaceutical company, committed to innovating cutting-edge discoveries in biotechnology and medicine.
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research and today our products are available in more than 100 countries. We are tirelessly dedicated to restoring brain health, so every person can be their best. The neuroscience market is on a growth trajectory. We see...
Lundbeck's Top Stability & Growth Strengths
Strong Revenue Growth: Feedback suggests total revenue increased at constant exchange rates across 2025 and into H1 2026, with double-digit gains in the U.S. and Europe supporting momentum.
Profitability: Earnings are considered to have scaled alongside revenue, with adjusted EBITDA rising materially, indicating improved profit leverage.
Product Line Growth: Strategic brands such as Vyepti and Rexulti are often cited as the primary engines of expansion, showing strong double-digit growth and contributing the majority of total revenue.
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have...
NKGen Biotech is a clinical-stage biotechnology company developing and commercializing natural killer (NK) cell therapies using its proprietary SNK platform. Its autologous, allogeneic, and CAR-NK candidates are intended to treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, as well as cancers. The company’s platform uses activated NK cells, which it aims to bring to patients through clinical development and eventual commercialization.
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to...
Anton Paar develops, produces, distributes and provides support for analytical instruments used in research, development and quality control worldwide. Ever since Mr. Anton Paar founded his one-man workshop in 1922, the Austrian based company has continuously found new ways to merge high-precision engineering with scientific curiosity. The company currently has more than 3500 employees and is active in over 170...
U.S. Dermatology Partners is one of the largest physician-owned dermatology practices in the United States, providing premier medical, surgical, and cosmetic skin care to over two million patients annually. With more than 130 locations across nine states, the organization focuses on patient-first care, combining the personalized experience of private practice with a coordinated network of specialized physicians and national thought...
Marathon Petroleum Corporation (MPC) is a leading, integrated, downstream energy company headquartered in Findlay, Ohio. The company operates the nation's largest refining system. MPC's marketing system includes branded locations across the United States, including Marathon brand retail outlets. MPC also owns the general partner and majority limited partner interest in MPLX LP, a midstream company that owns and operates gathering,...
Marathon Petroleum Corporation's Top Stability & Growth Strengths
Strong Revenue Growth: Quarterly revenue showed sharp momentum, with Q2 reaching approximately $52.3 billion versus roughly $34.1 billion a year earlier, while trailing 12-month trends point toward robust expansion as demand and utilization rebound.
Profitability: Earnings and profitability exceeded expectations, including Q2 EPS of $17.73 and full-year 2025 net income of $4.0 billion with adjusted EBITDA of $12.0 billion, supported by high crude capacity utilization near 94–95%.
Strategic Partnerships: Midstream expansion via MPLX underpins structural growth, with a $2.4 billion organic growth capital plan focused on natural gas and NGL infrastructure and expected distribution growth supporting dividends and capital spending.
Grupo Medinfar is a Portuguese pharmaceutical company founded in 1970, specializing in R&D, manufacturing, distribution, marketing, and sales of pharmaceutical products, cosmetics, and food supplements.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. We are powered...
Novo Nordisk's Top Stability & Growth Strengths
Strong Market Position & Advantage: Novo Nordisk is characterized as a global leader in GLP‑1–based diabetes and obesity care, anchored by clinically differentiated products like Wegovy and a broad GLP‑1 portfolio. While shares fluctuate by geography, disclosures and independent analyses continue to frame the company as a category leader.
Innovation-Driven Growth: Cardiovascular outcomes data supporting Wegovy’s label expansion and the first approved oral GLP‑1 for chronic weight management, together with late‑stage assets (e.g., amycretin/zenagamtide, CagriSema), strengthen adoption arguments and extend the franchise.
Market Expansion: U.S. launch momentum for the Wegovy pill, EU approval, and planned international rollouts in 2026 are broadening access and the addressable market. Significant capacity additions, including acquired fill‑finish sites and new investments, are intended to support higher volumes across regions.
Gemelli is a biotechnology company that specializes in the microbiome, and IBS diagnostics.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our pipeline includes tipifarnib, a farnesyl...
Xencor is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for patients with cancer and autoimmune diseases with unmet medical needs. Its XmAb protein-engineering platforms modify antibody Fc domains to improve biological function or create new therapeutic mechanisms, enabling purpose-built drug candidates. The company advances a broad portfolio through clinical development and also partners with biopharmaceutical companies...
The National MS Society is a non-profit organization dedicated to curing multiple sclerosis while empowering people affected by the disease to live their best lives through research, education, and support.
Sinclair is a global medical aesthetics company that specializes in manufacturing and commercializing a wide portfolio of injectable and EBD treatments to support a consumer's full aesthetic journey. As a wholly owned subsidiary of Huadong Medicine Company Limited, the company's products are available in more than 55 countries through a direct presence in key global markets and a network of...
Sinclair's Top Stability & Growth Strengths
Strong Market Position & Advantage: Sinclair is positioned as a top-tier U.S. broadcaster with one of the largest station portfolios and owned networks that extend national reach. It is widely characterized as a leading player in local TV and sports content, even as Nexstar holds the top spot.
Strong Revenue Growth: Recent 2026 quarters show year-over-year revenue gains and higher full-year guidance, supported by stronger political demand, improving local media trends, and stable distribution. Digital-led core advertising is noted as a contributor to the uptick.
Innovation-Driven Growth: The company plays a leading role in ATSC 3.0/NextGen TV through ONE Media and continues to build specialty assets such as Tennis Channel. These initiatives broaden technology and content platforms that can diversify growth beyond legacy broadcast.
Kyowa Kirin is a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines. We work on some of the hardest to treat diseases where need is high, and potential for life-changing impact is possible. The North America organization includes three offices in New Jersey and California that focus on drug discovery, product development, and commercialization. Together,...
Clean Energy pioneered renewable natural gas (RNG) as a vehicle fuel in the U.S. and we continue to be the largest provider of RNG for transportation. We have an extensive network of over 600 fueling stations across North America, and can deliver RNG to any station, public or private. RNG is the cleanest solution available today for heavy-duty trucks, transit...
PolyPeptide is a global Contract Development and Manufacturing Organization (CDMO) specializing in the development and manufacturing of peptide-based active pharmaceutical ingredients (APIs) and oligonucleotides. Serving pharmaceutical and biotech customers worldwide, the company supports the creation of therapies for metabolic diseases, cancer, and neurological disorders, contributing to the health of millions of patients through deep technical expertise and GMP-quality production.





























